Beam Therapeutics

General Information
Business:

 

We are a biotechnology company committed to creating a new class of precision genetic medicines based on our proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases. The most common class of genetic mutations are errors of a single base, known as point mutations. These point mutations represent approximately 58% of all the known genetic errors associated with disease. Other natural genetic variations of a single base among human populations, revealed by population-level genomic studies, are known to protect against disease. To maximize the impact of these genetic insights, the ability to alter the human genome at the foundational level of genetic information – a single base – is crucial.

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 87
Founded: 2017
Contact Information
Address 26 Landsdowne Street, 2nd Floor, Cambridge, MA 02139, US
Phone Number 857-327-8775.
Web Address http://www.beamtx.com
View Prospectus: Beam Therapeutics
Financial Information
Market Cap
Revenues $0 mil (last 12 months)
Net Income $-127.7 mil (last 12 months)
IPO Profile
Symbol BEAM
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $100.0 mil
Manager / Joint Managers J.P. Morgan/ Jefferies/ Barclays
CO-Managers Wedbush PacGrow
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change